Clal Biotechnology Industries Ltd. (TLV:CBI)
Israel
· Delayed Price · Currency is ILS · Price in ILA 31.10
+0.20 (0.64%)
May 7, 2025, 12:32 PM IDT
TLV:CBI Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | - | 0.1 | 0.37 | 0.22 | 0.21 | Upgrade
|
| Revenue Growth (YoY) | - | -71.89% | 65.18% | 8.74% | -99.82% | Upgrade
|
| Gross Profit | - | 0.1 | 0.37 | 0.22 | 0.21 | Upgrade
|
| Selling, General & Admin | 6.35 | 9.76 | 12.27 | 12.22 | 10.3 | Upgrade
|
| Operating Expenses | 6.63 | 10.29 | 12.88 | 12.87 | 10.85 | Upgrade
|
| Operating Income | -6.63 | -10.18 | -12.51 | -12.65 | -10.64 | Upgrade
|
| Interest Expense | -3.57 | -3.54 | -3.73 | -1.76 | - | Upgrade
|
| Interest & Investment Income | 0.17 | 0.13 | 0.01 | - | - | Upgrade
|
| Earnings From Equity Investments | -28.57 | -17 | -22.39 | -30.81 | -28.94 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.26 | 0.36 | 4.23 | -1.61 | -1.44 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.74 | -0.86 | -2.31 | 11.38 | 103.03 | Upgrade
|
| EBT Excluding Unusual Items | -39.07 | -31.09 | -36.69 | -35.44 | 62.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | -36 | 3 | -8.03 | -31.15 | 42.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 22.37 | Upgrade
|
| Other Unusual Items | - | - | 3.7 | - | - | Upgrade
|
| Pretax Income | -75.07 | -28.09 | -41.02 | -66.59 | 127.11 | Upgrade
|
| Earnings From Continuing Operations | -75.07 | -28.09 | -41.02 | -66.59 | 127.11 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -54.41 | -61.63 | -77.27 | Upgrade
|
| Net Income to Company | -75.07 | -28.09 | -95.43 | -128.21 | 49.84 | Upgrade
|
| Minority Interest in Earnings | 12.62 | -2.96 | 33.69 | 38.63 | 59.19 | Upgrade
|
| Net Income | -62.46 | -31.05 | -61.74 | -89.58 | 109.03 | Upgrade
|
| Net Income to Common | -62.46 | -31.05 | -61.74 | -89.58 | 109.03 | Upgrade
|
| Shares Outstanding (Basic) | 158 | 157 | 157 | 158 | 161 | Upgrade
|
| Shares Outstanding (Diluted) | 158 | 157 | 157 | 158 | 161 | Upgrade
|
| Shares Change (YoY) | 1.02% | - | -1.01% | -1.74% | 0.01% | Upgrade
|
| EPS (Basic) | -0.39 | -0.20 | -0.39 | -0.57 | 0.68 | Upgrade
|
| EPS (Diluted) | -0.39 | -0.20 | -0.39 | -0.57 | 0.68 | Upgrade
|
| Free Cash Flow | -6.48 | -8.52 | -60.31 | -42.92 | -36.41 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.05 | -0.39 | -0.27 | -0.23 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.220 | Upgrade
|
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | -9789.42% | -3380.00% | -5645.09% | -5166.02% | Upgrade
|
| Profit Margin | - | -29856.73% | -16686.49% | -39992.41% | 52925.73% | Upgrade
|
| Free Cash Flow Margin | - | -8190.39% | -16300.00% | -19160.71% | -17675.24% | Upgrade
|
| EBITDA | -6.35 | -10.03 | 5.14 | 9.87 | 13.23 | Upgrade
|
| EBITDA Margin | - | - | 1388.38% | 4404.46% | 6420.39% | Upgrade
|
| D&A For EBITDA | 0.28 | 0.15 | 17.64 | 22.51 | 23.87 | Upgrade
|
| EBIT | -6.63 | -10.18 | -12.51 | -12.65 | -10.64 | Upgrade
|
| Revenue as Reported | 8.57 | 39.73 | 18.03 | 55.26 | 168.58 | Upgrade
|
Updated Aug 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.